Potential Protein Blood-based Biomarkers in Different Types of Dementia: A Therapeutic Overview.

Current pharmaceutical design 2022

filter terms:

Biomarkers capable of identifying and distinguishing types of dementia, such as Alzheimer's disease (AD), Parkinson's disease dementia (PDD), Lewy body dementia (LBD), and frontotemporal dementia (FTD), have become increasingly relentless. Studies on possible biomarker proteins in the blood that can help formulate new diagnostic proposals and therapeutic visions of different types of dementia are needed. However, due to several limitations of these biomarkers, especially in discerning dementia, their clinical applications are still undetermined. Thus, updating biomarker blood proteins that can help in the diagnosis and discrimination of these main dementia conditions is essential to enable new pharmacological and clinical management strategies with specificities for each type of dementia. This paper aimed to review the literature concerning protein bloodbased AD and non-AD biomarkers as new pharmacological targets and/or therapeutic strategies. Recent findings related to protein-based AD, PDD, LBD, and FTD biomarkers are focused on in this review. Protein biomarkers are classified according to the pathophysiology of the dementia types. The diagnosis and distinction of dementia through protein biomarkers is still a challenge. The lack of exclusive biomarkers for each type of dementia highlights the need for further studies in this field. Only after this, blood biomarkers may have a valid use in clinical practice as they are promising to help in the diagnosis and in the differentiation of diseases. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Citation

Patricia R Manzine, Izabela P Vatanabe, Marina M Grigoli, Renata V Pedroso, Maria Patricia A O Monteiro, Danielle S M S Oliveira, Carla M C Nascimento, Rafaela Peron, Fabiana S Orlandi, Márcia R Cominetti. Potential Protein Blood-based Biomarkers in Different Types of Dementia: A Therapeutic Overview. Current pharmaceutical design. 2022;28(14):1170-1186